Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Curis Stock Perked Up in August

TheMotleyFool

0 0

Why Curis Stock Perked Up in AugustPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Curis (NASDAQ: CRIS), a small-cap cancer specialist, posted a healthy gain in August. The biotech's shares rose by 16.6% last month, according to data provided by S&P Global Market Intelligence.

What sparked this double-digit move higher? Curis' shares appeared to be a direct beneficiary of Pfizer's (NYSE: PFE) buyout of Trillium Therapeutics (NASDAQ: TRIL), another small-cap cancer company with an early-stage pipeline.

Curis' shares were essentially trading sideways during the early part of the month, but they quickly came to life in the aftermath of Pfizer's acquisition of Trillium on Aug. 23. In fact, Curis' stock gained a noteworthy 15.4% in the final week of the month.

Source Fool.com

Like: 0

CRIS

Share